https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38755542&retmode=xml&tool=Litmetric&email=readroberts32@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38755542</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study.</ArticleTitle><Pagination><StartPage>596</StartPage><MedlinePgn>596</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">596</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-024-12297-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Oesophageal squamous cell carcinoma is one of the most commonly diagnosed carcinomas in China, and postoperative radiotherapy plays an important role in improving the prognosis of patients. Carcinomas in different locations of the oesophagus could have different patterns of lymph node metastasis after surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this multicentric retrospective study, we enrolled patients with middle thoracic oesophageal squamous cell carcinomas from 3 cancer centres, and none of the patients underwent radiotherapy before or after surgery. We analysed the lymph node recurrence rates in different stations to explore the postoperative lymphatic recurrence pattern.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">From January 1st, 2014, to December 31st, 2019, 132 patients met the criteria, and were included in this study. The lymphatic recurrence rate was 62.1%. Pathological stage (P&#x2009;=&#x2009;0.032) and lymphadenectomy method (P&#x2009;=&#x2009;0.006) were significant predictive factors of lymph node recurrence. The recurrence rates in the supraclavicular, upper and lower paratracheal stations of lymph nodes were 32.6%, 28.8% and 16.7%, respectively, showing a high incidence. The recurrence rate of the subcarinal node station was 9.8%, while 8.3% (upper, middle and lower) thoracic para-oesophageal nodes had recurrences.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We recommend including the supraclavicular, upper and lower paratracheal stations of lymph nodes in the postoperative radiation field in middle thoracic oesophageal carcinomas. Subcarinal station is also potentially high-risk, while whether to include thoracic para-oesophageal or abdominal nodes needs careful consideration.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Du</LastName><ForeName>Rongxu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Fan</LastName><ForeName>Songqing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oncology Division I, China Pingmei Shenma Medical Group General Hospital, Kuanggongzhong Rd.1, Xinhua District, Pingdingshan Henan, 450052, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaobin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hebei Cancer Hospital, The Fourth Hospital of Hebei Medical University, JianKang Rd.12, Shijiazhuang Hebei, 050011, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Xia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, Shanxi, 030013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Central Theater General Hospital, Wuluo Rd. 627, Wuchang District, Wuhan Hubei, 430061, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, Shanxi, 030013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Rongrong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, Shanxi, 030013, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Leilei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Rong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Huiming</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhu</LastName><ForeName>Shuchai</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Hebei Cancer Hospital, The Fourth Hospital of Hebei Medical University, JianKang Rd.12, Shijiazhuang Hebei, 050011, China. sczhu1965@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, No.3 Workers New Village, Xinghualing District, Taiyuan, Shanxi, 030013, China. lijie942003@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Shi</LastName><ForeName>Anhui</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital &amp; Institute, Beijing, 100142, China. anhuidoctor@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Y-2019AZMS-0519</GrantID><Agency>CSCO grant</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004938" MajorTopicYN="Y">Esophageal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="Y">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="Y">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="Y">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="Y">Lymph Node Excision</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077277" MajorTopicYN="Y">Esophageal Squamous Cell Carcinoma</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016629" MajorTopicYN="N">Esophagectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Middle thoracic oesophageal carcinoma</Keyword><Keyword MajorTopicYN="N">Postoperative lymph node recurrence</Keyword><Keyword MajorTopicYN="N">Radiation field</Keyword><Keyword MajorTopicYN="N">Real-world study</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>0</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>16</Day><Hour>23</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38755542</ArticleId><ArticleId IdType="pmc">PMC11097414</ArticleId><ArticleId IdType="doi">10.1186/s12885-024-12297-4</ArticleId><ArticleId IdType="pii">10.1186/s12885-024-12297-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GLOBOCAN 2020. oesophagus cancer fact sheet [https://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf].</Citation></Reference><Reference><Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394&#x2013;424. doi: 10.3322/caac.21492.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21492</ArticleId><ArticleId IdType="pubmed">30207593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. Cancer J Clin. 2016;66(2):115&#x2013;32. doi: 10.3322/caac.21338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21338</ArticleId><ArticleId IdType="pubmed">26808342</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends&#x2013;an update. Cancer Epidemiol Biomark Prev. 2016;25(1):16&#x2013;27. doi: 10.1158/1055-9965.EPI-15-0578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1055-9965.EPI-15-0578</ArticleId><ArticleId IdType="pubmed">26667886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598&#x2013;606. doi: 10.3748/wjg.v19.i34.5598.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v19.i34.5598</ArticleId><ArticleId IdType="pmc">PMC3769895</ArticleId><ArticleId IdType="pubmed">24039351</ArticleId></ArticleIdList></Reference><Reference><Citation>Forastiere AA. Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus. 2010;7(1):1&#x2013;6. doi: 10.1007/s10388-009-0226-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10388-009-0226-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertier. multi-directional interpretation of esophageal cancer standardized diagnosis and treatment [http://news.medlive.cn/cancer/info-progress/show-40985_53.html].</Citation></Reference><Reference><Citation>Chen J, Pan J, Zheng X, Zhu K, Li J, Chen M, Wang J, Liao Z. Number and location of positive nodes, postoperative radiotherapy, and survival after esophagectomy with three-field lymph node dissection for thoracic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(1):475&#x2013;82. doi: 10.1016/j.ijrobp.2010.08.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2010.08.037</ArticleId><ArticleId IdType="pubmed">20934269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AT, Shao M, Rineer J, Lee A, Schwartz D, Schreiber D. The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma. Ann Surg. 2017;265(6):1146&#x2013;51. doi: 10.1097/SLA.0000000000001825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001825</ArticleId><ArticleId IdType="pubmed">27280504</ArticleId></ArticleIdList></Reference><Reference><Citation>Worni M, Martin J, Gloor B, Pietrobon R, D&#x2019;Amico TA, Akushevich I, Berry MF. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg. 2012;215(5):643&#x2013;51. doi: 10.1016/j.jamcollsurg.2012.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2012.07.006</ArticleId><ArticleId IdType="pmc">PMC3479433</ArticleId><ArticleId IdType="pubmed">23084493</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou B, Pang J, Liu Y, Xu Y, Li L, Zhou L, Zhu J, Huang M, Wang J, Ren L, et al. Postoperative chemoradiotherapy improves survival in patients with stage II-III esophageal squamous cell carcinoma: an analysis of clinical outcomes. Thorac cancer. 2016;7(5):515&#x2013;21. doi: 10.1111/1759-7714.12355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.12355</ArticleId><ArticleId IdType="pmc">PMC5129165</ArticleId><ArticleId IdType="pubmed">27766781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Wang Z, Yang Z, Liu Y, Liu X, Shang B, Jiang WP. Postoperative radiotherapy improves survival in stage pT2N0M0 esophageal squamous cell carcinoma with high risk of poor prognosis. Ann Surg Oncol. 2016;23(1):265&#x2013;72. doi: 10.1245/s10434-015-4622-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-015-4622-0</ArticleId><ArticleId IdType="pubmed">26014154</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Ouyang W, Li Y, Hu J, Xu Y, Wei Y, Liao Z, Liu Y, Zhang J, Xie C. Value of radiotherapy in addition to esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma: analysis of surveillance, epidemiology, and end results database. Cancer Med. 2019;8(1):21&#x2013;7. doi: 10.1002/cam4.1731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1731</ArticleId><ArticleId IdType="pmc">PMC6346254</ArticleId><ArticleId IdType="pubmed">30561117</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Guidelines for Radiotherapy of Esophageal Cancer. Journal of International Oncology, 2022. 2022;49(11):641&#x2013;657.</Citation></Reference><Reference><Citation>Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncology: Official Publication Int Association Study Lung Cancer. 2017;12(1):36&#x2013;42. doi: 10.1016/j.jtho.2016.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2016.10.016</ArticleId><ArticleId IdType="pmc">PMC5591443</ArticleId><ArticleId IdType="pubmed">27810391</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Kemuriyama K, Sasaki Y, Imai K, Maeda E, Minamiya Y. PET-uptake reduction into lymph nodes after neoadjuvant therapy is highly predictive of prognosis for patients who have thoracic esophageal squamous cell carcinoma treated with chemoradiotherapy plus esophagectomy. Ann Surg Oncol. 2022;29(2):1336&#x2013;46. doi: 10.1245/s10434-021-10564-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1245/s10434-021-10564-3</ArticleId><ArticleId IdType="pubmed">34355333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamoto T, Nihei K, Sasai K, Karasawa K. Clinical outcomes and prognostic factors of chemoradiotherapy for postoperative lymph node recurrence of esophageal cancer. Jpn J Clin Oncol. 2018;48(3):259&#x2013;64. doi: 10.1093/jjco/hyx171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jjco/hyx171</ArticleId><ArticleId IdType="pubmed">29190352</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z-C, Su B-A. Comparison of local recurrence patterns of postoperative radiotherapy with surgery alone for esophageal carcinoma patients. J Surg Oncol. 2021;6(1):33&#x2013;40.</Citation></Reference><Reference><Citation>Li J, Qiu R, Hu Y, Wang Y, Qi Z, He M, Li Y. Postoperative adjuvant therapy for patients with pN&#x2009;+&#x2009;esophageal squamous cell carcinoma. BioMed research international. 2021;2021:8571438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847342</ArticleId><ArticleId IdType="pubmed">33553432</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, Chen J, Xiao Z, Yu S, Zhang W, Zhou Z, Chen D, Feng Q, Chen X, Lin Y, et al. Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: results from a Chinese two-center study. Thorac cancer. 2019;10(6):1431&#x2013;40. doi: 10.1111/1759-7714.13088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1759-7714.13088</ArticleId><ArticleId IdType="pmc">PMC6558505</ArticleId><ArticleId IdType="pubmed">31102336</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Zhao L, Lin B, Su H, Su M, Xie D, Jin X, Xie C. Adjuvant therapeutic modalities following three-field lymph node dissection for stage II/III esophageal squamous cell carcinoma. J Cancer. 2017;8(11):2051&#x2013;9. doi: 10.7150/jca.18981.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/jca.18981</ArticleId><ArticleId IdType="pmc">PMC5559967</ArticleId><ArticleId IdType="pubmed">28819406</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R, Fan S, Wang X, Hou X, Zeng C, Guo D, Tian R, Yang D, Jiang L, Dong X, et al. Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study. Radiation Oncol (London England) 2022;17(1):47. doi: 10.1186/s13014-022-01987-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13014-022-01987-7</ArticleId><ArticleId IdType="pmc">PMC8898421</ArticleId><ArticleId IdType="pubmed">35248100</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Gao J, Zheng A, Yang H, Li J, Wu S, Zhao J, Meng P, Zhou F. Definition and risk factors of early recurrence based on affecting prognosis of esophageal squamous cell carcinoma patients after radical resection. Translational Oncol. 2021;14(6):101066. doi: 10.1016/j.tranon.2021.101066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2021.101066</ArticleId><ArticleId IdType="pmc">PMC7985560</ArticleId><ArticleId IdType="pubmed">33744728</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W, Li B, Gong H, Yu J, Zhou T, Sun H, Zhang Z, Liu X. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases. Radiother Oncol. 2010;95(2):229&#x2013;33. doi: 10.1016/j.radonc.2010.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radonc.2010.01.006</ArticleId><ArticleId IdType="pubmed">20189259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X, He J. Cancer incidence and mortality in China, 2014. Chin J cancer Res = Chung-kuo Yen Cheng Yen Chiu. 2018;30(1):1&#x2013;12. doi: 10.21147/j.issn.1000-9604.2018.01.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.21147/j.issn.1000-9604.2018.01.01</ArticleId><ArticleId IdType="pmc">PMC5842223</ArticleId><ArticleId IdType="pubmed">29545714</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu AJ, Bosch WR, Chang DT, Hong TS, Jabbour SK, Kleinberg LR, Mamon HJ, Thomas CR, Jr, Goodman KA. Expert consensus contouring guidelines for intensity modulated radiation therapy in esophageal and gastroesophageal junction cancer. Int J Radiat Oncol Biol Phys. 2015;92(4):911&#x2013;20. doi: 10.1016/j.ijrobp.2015.03.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijrobp.2015.03.030</ArticleId><ArticleId IdType="pmc">PMC4481325</ArticleId><ArticleId IdType="pubmed">26104943</ArticleId></ArticleIdList></Reference><Reference><Citation>Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996;83(1):107&#x2013;11. doi: 10.1002/bjs.1800830134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bjs.1800830134</ArticleId><ArticleId IdType="pubmed">8653330</ArticleId></ArticleIdList></Reference><Reference><Citation>Katayama A, Mafune K, Tanaka Y, Takubo K, Makuuchi M, Kaminishi M. Autopsy findings in patients after curative esophagectomy for esophageal carcinoma. J Am Coll Surg. 2003;196(6):866&#x2013;73. doi: 10.1016/S1072-7515(03)00116-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1072-7515(03)00116-9</ArticleId><ArticleId IdType="pubmed">12788422</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198(2):205&#x2013;11. doi: 10.1016/j.jamcollsurg.2003.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2003.10.005</ArticleId><ArticleId IdType="pubmed">14759776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda T, Yano M, Miyata H, Yamasaki M, Takiguchi S, Fujiwara Y, Doki Y. Evaluation of dysphagia and diminished airway protection after three-field esophagectomy and a remedy. World J Surg. 2013;37(2):416&#x2013;23. doi: 10.1007/s00268-012-1822-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-012-1822-7</ArticleId><ArticleId IdType="pubmed">23052815</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita K, Watanabe M, Mine S, Kurogochi T, Okamura A, Hayami M, Imamura Y. Patterns and outcomes of recurrent esophageal cancer after curative esophagectomy. World J Surg. 2017;41(9):2337&#x2013;44. doi: 10.1007/s00268-017-4024-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00268-017-4024-5</ArticleId><ArticleId IdType="pubmed">28432391</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Hu H, Zhang Y, Zhang J, Miao L, Ma L, Luo X, Zhang Y, Ye T, Li H. Three-field versus two&#x2010;field lymphadenectomy in transthoracic oesophagectomy for oesophageal squamous cell carcinoma: short&#x2010;term outcomes of a randomized clinical trial. Br J Surg 2020, 107.</Citation><ArticleIdList><ArticleId IdType="pubmed">32108326</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220(3):364&#x2013;72. doi: 10.1097/00000658-199409000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199409000-00012</ArticleId><ArticleId IdType="pmc">PMC1234394</ArticleId><ArticleId IdType="pubmed">8092902</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, Fujii T, Yamasaki K, Higaki K, Noake T. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg. 1995;222(5):654&#x2013;62. doi: 10.1097/00000658-199511000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000658-199511000-00008</ArticleId><ArticleId IdType="pmc">PMC1234993</ArticleId><ArticleId IdType="pubmed">7487213</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies AR, Pillai A, Sinha P, Sandhu H, Adeniran A, Mattsson F, Choudhury A, Forshaw MJ, Gossage JA, Lagergren J, et al. Factors associated with early recurrence and death after esophagectomy for cancer. J Surg Oncol. 2014;109(5):459&#x2013;64. doi: 10.1002/jso.23511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jso.23511</ArticleId><ArticleId IdType="pubmed">24301461</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu ZJ, Hu Y, Zhao YF, Chen XZ, Chen LQ, Chen YT. Early recurrence and death after esophagectomy in patients with esophageal squamous cell carcinoma. Ann Thorac Surg. 2011;91(5):1502&#x2013;8. doi: 10.1016/j.athoracsur.2011.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2011.01.007</ArticleId><ArticleId IdType="pubmed">21354552</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang KY, Huang H, Chen WY, Yan HJ, Wei ZT, Wang XW, Li HX, Zheng XY, Tian D. Risk factors for lymph node metastasis in T1 esophageal squamous cell carcinoma: a systematic review and meta-analysis. World J Gastroenterol. 2021;27(8):737&#x2013;50. doi: 10.3748/wjg.v27.i8.737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v27.i8.737</ArticleId><ArticleId IdType="pmc">PMC7934003</ArticleId><ArticleId IdType="pubmed">33716451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>